Zydus Cadila, an Ahmedabad-based innovative, global pharmaceutical company, announced that the company will be making a presentation on Lipaglyn at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific and Clinical Congress to be held May 13 to 17, 2015 at Nashville, Tennessee, USA. The abstract titled ‘9-month safety and efficacy of saroglitazar in diabetic dyslipidemia’ has been accepted for late breaking presentation at the AACE meeting.

Speaking on the development, Pankaj R. Patel, chairman and managing director, Zydus Group said, “The robust scientific data on safety and efficacy of saroglitazar in diabetic dyslipidemia accepted for presentation at this year’s AACE meeting reflects our continued commitment to patients suffering from diabetes and dyslipidemia. Because of its unique mechanism of action, we see huge potential of Saroglitazar in treating non-alcoholic steatohepatitis (NASH)  and going further we will develop this important therapeutic for millions of patients suffering from fatty liver disease”.

Lipaglyn (saroglitazar) was launched in September 2013 in India, for treating hypertriglyceridemia and diabetic dyslipidemia in patients with type 2 diabetes not controlled by statins. Since then, more than 80,000 patients are availing this drug with a prescriber base over 3500 diabetologists, cardiologists and physicians. Lipaglyn helps in a reduction of triglycerides and LDL (bad) cholesterol, and an increase in HDL (good) cholesterol and has also shown a reduction in fasting plasma glucose and glycosylated haemoglobin (HbA1c), thereby confirming its beneficial effects on both lipid and glycemic control in diabetic patients. Lipaglyn is a prescription medicine, and can be taken only under the advice and guidance of a registered medical practitioner.